Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality.
OBJECTIVE
It has been documented that testicular germ cell cancer (TGCC) patients may be at increased risk of developing emotional distress (EMD). Hence, the aim of the present study was to investigate whether EMD is related to the presence of hypogonadism, androgen receptor (AR) polymorphism and/or treatment intensity.


METHODS
Three to five years after treatment, testosterone and luteinizing hormone (LH) levels were measured in 165 TGCC patients. These patients also completed a questionnaire concerning mental health. EMD was measured by the Hospital Anxiety and Depression Scale (HADS). The androgen receptor (AR) gene has two polymorphic regions in exon I; glutamine encoding CAG and glycine encoding GGN repeats. Association between emotional disorders and AR polymorphisms as well as type of treatment was assessed.


RESULTS
Neither anxiety (OR 1.0; 95% CI 0.40-2.4) nor depression (OR 1.1; 95% CI 0.20-6.4) were overrepresented in biochemically hypogonadal TGCC patients and no association between AR polymorphisms and EMD was found. Patients treated with >or=5 cycles of cisplatinum based chemotherapy due to refractory or relapsed disease were more prone to experiencing symptoms of anxiety (p=0.006), but not depression (p=0.38).


CONCLUSIONS
Biochemical hypogonadism and AR polymorphism do not seem to be risk factors for EMD in TGCC patients. Patients with refractory or relapsed disease receiving >or=5 cycles of cisplatinum based chemotherapy may, to a higher degree than patients receiving less intense therapy, suffer from anxiety.
Eberhard
Jakob
J
Department of Oncology, Lund University Hospital, Lund University, SE 221 85 Lund, Sweden. jakob.eberhard@med.lu.se
Ståhl
Olof
O
Cohn-Cedermark
Gabriella
G
Cavallin-Ståhl
Eva
E
Giwercman
Yvonne
Y
Rastkhani
Hamideh
H
Rylander
Lars
L
Eberhard-Gran
Malin
M
Kvist
Ulrik
U
Giwercman
Aleksander
A
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001007:Anxiety / Q000209:etiology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003863:Depression / Q000209:etiology; D020022:Genetic Predisposition to Disease; D018237:Germinoma / Q000378:metabolism / Q000523:psychology; D006801:Humans; D007006:Hypogonadism / Q000150:complications* / Q000209:etiology / Q000523:psychology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D019964:Mood Disorders / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000523:psychology; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic; D011944:Receptors, Androgen / Q000235:genetics*; D012008:Recurrence; D012307:Risk Factors; D011795:Surveys and Questionnaires; D017741:Survivors / Q000523:psychology; D013548:Sweden; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000523:psychology*; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D000970:Antineoplastic Agents; D011944:Receptors, Androgen; D013739:Testosterone; D007986:Luteinizing Hormone; D002945:Cisplatin